Press Releases

Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results

CARLSBAD, Calif., Feb. 7, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced results for the quarter and full year ended December 31, 2011 and provided financial guidance for 2012.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

"I am pleased with our performance in the fourth quarter and throughout 2011, even as we faced a number of challenges, including macroeconomic headwinds and constrained spending by some of our customers," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. "Overcoming these obstacles, we delivered top line growth, reduced our operating costs to meet the slower growth environment and expanded our operating margins an impressive 110 basis points, all of which we leveraged to deliver bottom line growth for the twelfth consecutive year. We finished the year with strong free cash flow of $710 million."

"Looking ahead to 2012, we expect growth in our game-changing Ion Torrent franchise, expansion in end markets and geographies and continued operational efficiencies to drive organic revenue growth of 2 to 4 percent over 2011 results and adjusted non-GAAP EPS in a range of $3.90 to $4.05."

Life Technologies reported results compared to quarter and year ended December 31, 2010.

Analysis of Fourth Quarter 2011 and Fiscal Year 2011 Results

  • Fourth quarter non-GAAP 2011 revenue increased 4 percent, or 3 percent excluding the impact from currency, with particularly strong growth in sales of Ion Torrent and Forensics. Full year non-GAAP 2011 revenue increased 4 percent, or 3 percent excluding the impact from currency, driven by increased sales of Ion Torrent, BioProduction and Forensics.  The increase in both periods was partially offset by a decrease in sales of SOLiD products.
  • Non-GAAP gross margin in the fourth quarter increased 20 basis points to 64.8 percent, driven primarily by realized price and increased manufacturing productivity, which were partially offset by product mix and the termination of a supply agreement.  Full year non-GAAP gross margin was 65.3 percent, a decrease of 150 basis points, due to currency hedging losses, upgrades to our SOLiD 5500 and Ion Torrent sales, which were partially offset by realized price and manufacturing productivity.
  • Non-GAAP operating margin increased 470 basis points to 31 percent in the fourth quarter, representing an all time high for the Company.  Full year operating margin increased 40 basis points to 29.1 percent and, excluding currency, expanded 110 basis points. The increase in both periods resulted from a reduction in operating expenses including cost savings initiatives, a portion of which was offset by expenses related to developing Ion Torrent.
  • The non-GAAP tax rate was 26.8 percent for the fourth quarter and 27.3 percent for the full year.
  • Fourth quarter non-GAAP EPS increased 18 percent to $1.06. Full year non-GAAP EPS increased 5 percent to $3.73 .
  • Diluted weighted shares outstanding were 184.5 million in the fourth quarter.
  • Cash flow from operating activities for the fourth quarter was $316 million.  Fourth quarter capital expenditures were $34 million and resulting free cash flow was $282 million. The company ended the quarter with $882 million in cash and short-term investments.

Business Highlights:

  • Genetic Systems division non-GAAP revenue increased 13 percent to $278 million in the fourth quarter, or 11 percent excluding the impact from currency.  Growth in the current year quarter was driven by increased sales of Ion Torrent and double digit growth in Forensics, which was partially offset by reduced sales of SOLiD products.  Full year non-GAAP revenue increased 8 percent to $1 billion, or 7 percent excluding the impact from currency.  Growth for the full year period was driven by increased sales of Ion Torrent franchise, growth in Forensics and Capillary Electrophoresis, all of which was partially offset by lower growth in SOLiD products.
  • Molecular Biology Systems division non-GAAP revenue decreased 1 percent to $441 million in the fourth quarter, or 2 percent excluding the impact of currency.  The decline in the current year quarter resulted from a decline in qPCR royalties and continued lower spending by academic customers.  Full year non-GAAP revenue was $1.7 billion, flat compared to the prior year period, and decreased 2 percent excluding the impact of currency. The decrease for the full year was the result of lower qPCR royalties, slower funding which drove lower PCR sales and a disruption in China sales as the company transitioned certain dealer networks to direct sales during the second quarter of 2011.
  • Cell Systems division non-GAAP revenue increased 3 percent to $244 million in the fourth quarter, or 1 percent excluding the impact of currency, compared to a strong fourth quarter of 2010. Growth in the fourth quarter was driven by increased sales of cell culture products and by increased sales in BioProduction. Full year non-GAAP revenue increased 7 percent to $969 million, or 6 percent excluding the impact of currency.  Full year growth was driven by increased BioProduction sales and sales across our cell consumables businesses.
  • Regional organic growth rates for the quarter were as follows: the Americas was flat, Europe grew 4 percent, Asia Pacific grew 10 percent and Japan grew 4 percent.  Full year growth rates were as follows: the Americas was 2%, Europe grew 3 percent, Asia Pacific 9 percent, and Japan declined 3 percent.  
  • Revenue from orders transacted through Life Technologies' eCommerce channels grew approximately 8 percent during the quarter and approximately 12 percent for the full year. Over 50 percent of all transactions globally are processed using eCommerce platforms.

Changes in Reporting

The company plans to modify its reporting to better align with changes it has made in its internal organization. These changes have no impact on results of operations, financial condition or cash flows of the Company as a whole.

The company currently reports revenues for three divisions: Molecular Biology Systems, Genetic Systems and Cell Systems. Starting in the first quarter of 2012, the company will report revenues for the following three business groups: Research Consumables, Genetic Analysis and Applied Sciences. These changes will be finalized during and effective for the first quarter of 2012 and the company will provide revised financial data reflecting these changes prior to reporting its first quarter results in April 2012.

Fiscal Year 2012 Outlook

Subject to the risk factors detailed in the Safe Harbor Statement section of this release, the company provided its expectations for fiscal year 2012 financial performance. The company expects organic revenue growth of 2 to 4 percent over 2011 revenues of $3.7 billion and non-GAAP earnings per share to be in a range of $3.90 to $4.05. The guidance includes a revenue headwind of approximately $26 million, or 0.7 percent, and a benefit to non-GAAP EPS of approximately $0.02 from currency. The currency impact consists of a negative effect from changes in currency exchange rates based on December 2011 month end rates, partially offset by a benefit from not having the hedge losses that occurred in 2011. The company will provide further detail on its business outlook during the webcast today.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products.  Life Technologies had sales of $3.7 billion in 2011, employs approximately 10,400 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 4,000 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: www.lifetechnologies.com.

Safe Harbor Statement

Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and Life Technologies intend that such forward-looking statements be subject to the safe harbor created thereby.  Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of  the company. Such forward-looking statements include, but are not limited to, statements relating to financial projections, including revenue and pro forma EPS projections; success of acquired businesses, including cost and revenue synergies; development and increased flow of new products; leveraging technology and personnel; advanced opportunities and efficiencies; opportunities for growth; expectations of prospective new standards, new delivery platforms, and new selling specialization and effectiveness; and corporate strategy and performance.  A number of the matters discussed in this press release and presentation that are not historical or current facts deal with potential future circumstances and developments, including future research and development plans. The discussion of such matters is qualified by the inherent risks and uncertainties surrounding future expectations generally and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to:  volatility of the financial markets; and the risks that are described from time to time in Life Technologies' reports filed with the SEC.  This press release and presentation speaks only as of its date, and the company disclaims any duty to update the information herein.

Non-GAAP Measurements

This press release includes certain financial information which constitutes "non-GAAP financial measures" as defined by the SEC.  The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these measures with the most directly comparable GAAP measures, can be found at on the Investor Relations portion of the company's website at www.lifetechnologies.com.

Investor and Financial Contact:

Carol Cox
Investor Relations
(760) 603-7208
ir@lifetech.com

LIFE TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

AND RECONCILIATION OF NON-GAAP ADJUSTMENTS(1)


















For the three months


For the three months

(in thousands, except per share data)

ended December 31, 2011


ended December 31, 2010

(unaudited)














GAAP

Adjustments

Non-GAAP


GAAP

Adjustments

Non-GAAP

Revenues


$ 1,010,445

$ (40,106)

(2)

$  970,339


$ 932,337

$     1,301

(2)

$  933,638

Cost of revenues

345,305

(3,855)

(3)

$  341,450


330,940

(104)

(3)

330,836

Purchased intangibles amortization

82,201

(82,201)

(4)

    -


83,401

(83,401)

(4)

    -




Gross profit

582,939

45,950


628,889


517,996

84,806


602,802

Gross margin

57.7%



64.8%


55.6%



64.6%

Operating expenses:











Selling, general and administrative

249,535

(5,864)

(5)

243,671


270,001

(11,200)

(5)

258,801


Research and development

90,201

(5,587)

(5)

84,614


108,711

(10,119)

(5)

98,592


Business consolidation costs

18,856

(18,856)

(6)

    -


27,025

(27,025)

(6)

    -



Total operating expenses

358,592

(30,307)


328,285


405,737

(48,344)


357,393




Operating income

224,347

76,257


300,604


112,259

133,150


245,409

Operating margin

22.2%



31.0%


12.0%



26.3%


Interest income

972



972


678



678


Interest expense

(38,162)

6,649

(7)

(31,513)


(36,289)

8,617

(7)

(27,672)


Other income (expense), net

(2,933)

    -


(2,933)


385

(559)

(8)

(174)



Total other income (expense), net

(40,123)

6,649


(33,474)


(35,226)

8,058


(27,168)

Income from operations before provision for










    income taxes

184,224

82,906


267,130


77,033

141,208


218,241

Income tax provision

(56,871)

(14,814)

(9)

(71,685)


(6,465)

(39,466)

(9)

(45,931)




Net income

127,353

68,092


195,445


70,568

101,742


172,310




Net loss attributable to non-controlling interests

    -

    -


    -


113

(98)

(10)

15




Net income attributable to controlling interest

$    127,353

$  68,092


$  195,445


$   70,681

$ 101,644


$  172,325














Effective tax rate

30.9%



26.8%


8.4%



21.0%

Add back interest expense for subordinated










   debt, net of tax

584

(551)

(11)

33


    -



    -

Numerator for diluted earnings










 per share

$    127,937

$  67,541


$  195,478


$   70,681

$ 101,644


$  172,325














Earnings per common share:











Basic earnings per share attributable to controlling interest

$          0.71



$        1.10


$       0.38



$        0.93















Diluted earnings per share attributable to controlling interest

$          0.69



$        1.06


$       0.37



$        0.90














Weighted average shares used in per share calculation:











Basic


178,304



178,304


186,046



186,046


Diluted


184,544



184,544


191,227



191,227




(1)


The Company reports Non-GAAP results which exclude costs that are not indicative of the profitability or cash flows of the Company's ongoing or future operations.  Such costs include restructuring charges, business transformation expenses, amortization and depreciation of deferred revenue, intangibles assets, and fixed assets,  revaluation charges for inventories, contingent consideration liabilities,  and asset impairments, and in process research and development expenses incurred as a result of business combinations, as well as the impact from the divestiture and discontinuance of product lines.  The Company also excludes noncash interest expense associated with convertible debt bifurcation and noncash charges associated with non-controlling interests.  In addition, the Company excludes one-time costs including the early repayment of debt and the associated impacts, and the impact of certain settlements in order to provide a supplemental comparison of the results of operations.




(2)


Adjust for royalty revenue recognized upon a historical and current licensing settlement of $38.8 million and revenue related to credit usage on returns of a discontinued product of $1.8 million, offset with fair value amortization of purchased deferred revenue of $0.5 million for the three months ended December 31, 2011.  Add back fair value amortization of purchased deferred revenue of $1.3 million for the three months ended December 31, 2010.




(3)


Add back royalty fees and expenses of $4.5 million related to the historical portion of the settlement of a licensing dispute, offset with contingent consideration revaluation of $0.6 million for the three months ended December 31, 2011.  Add back noncash charges for purchase accounting inventory revaluations cost of $0.1 million for the three months ended December 31, 2010.




(4)


Add back amortization of purchased intangibles.




(5)


Add back $10.0 million for expenses and an asset impairment partially offset by recovery of expenses related to the historical portion of the settlement of a licensing dispute and depreciation of purchase accounting property, plant, and equipment revaluations of $1.5 million for the three months ended December 31, 2011.  Add back depreciation of purchase accounting property, plant, and equipment revaluations of $2.4 million and accelerated compensation expenses related to business acquisitions of $18.9 million for the three months ended December 31, 2010.




(6)


Add back business consolidation costs.




(7)


Add back charges related to noncash interest expense as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options of $5.1 million and $7.1 million for the three months ended December 31, 2011 and 2010, respectively.  Adjust for imputed finance charges of $1.5 million associated with contingent consideration on business acquisitions for each of the three months ended December 31, 2011 and 2010.




(8)


Adjust for a discontinuance gain recognized on cash flow hedge of $0.6 million for the three months ended December 31, 2010.




(9)


Non-GAAP tax differs from GAAP tax expense due to the exclusion of the aforementioned business combination related charges, non cash charges, and one-time costs which are not indicative of the profitability or cash flows of the Company's ongoing or future operations.  These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation.




(10)

Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant, and equipment revaluations attributable to non-controlling interest, net of tax benefit.



(11)


Eliminate noncash interest charges from diluted earnings per share calculation, as the noncash interest is excluded from the calculation of Non-GAAP net income.



LIFE TECHNOLOGIES CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

AND RECONCILIATION OF NON-GAAP ADJUSTMENTS(1)


















For the year ended


For the year ended

(in thousands, except per share data)

December 31, 2011


December 31, 2010

(unaudited)














GAAP

Adjustments

Non-GAAP


GAAP

Adjustments

Non-GAAP

Revenues


$ 3,775,672

$ (34,995)

(2)

$ 3,740,677


$ 3,588,094

$     6,746

(2)

$ 3,594,840

Cost of revenues

1,301,145

(4,394)

(3)

$ 1,296,751


1,188,199

5,360

(3)

1,193,559

Purchased intangibles amortization

308,728

(308,728)

(4)

    -


293,754

(293,754)

(4)

    -




Gross profit

2,165,799

278,127


2,443,926


2,106,141

295,140


2,401,281

Gross margin

57.4%



65.3%


58.7%



66.8%

Operating expenses:











Selling, general and administrative

1,008,973

(10,776)

(5)

998,197


1,023,179

(17,096)

(5)

1,006,083


Research and development

377,924

(21,561)

(5)

356,363


375,465

(12,208)

(5)

363,257


Purchased in-process research and development

-

-


-


1,650

(1,650)

(4)

-


Business consolidation costs

75,324

(75,324)

(6)

    -


93,450

(93,450)

(6)

    -



Total operating expenses

1,462,221

(107,661)


1,354,560


1,493,744

(124,404)


1,369,340




Operating income

703,578

385,788


1,089,366


612,397

419,544


1,031,941

Operating margin

18.6%



29.1%


17.1%



28.7%


Interest income

3,932

-


3,932


4,266

-


4,266


Interest expense

(162,073)

30,779

(7)

(131,294)


(152,322)

39,582

(7)

(112,740)


Loss on early retirement of debt

-

-


-


(54,185)

54,185

(8)

-


Gain on divestiture of equity investments

-

-


-


37,260

(37,260)

(9)

-


Other income (expense), net

(10,913)

    -


(10,913)


(5,864)

5,500

(10)

(364)



Total other income (expense), net

(169,054)

30,779


(138,275)


(170,845)

62,007


(108,838)

Income from operations before provision for










    income taxes

534,524

416,567


951,091


441,552

481,551


923,103

Income tax provision

(122,405)

(137,424)

(11)

(259,829)


(63,694)

(182,994)

(11)

(246,688)




Net income

412,119

279,143


691,262


377,858

298,557


676,415




Net loss attributable to non-controlling interests

658

(308)

(12)

350


437

(290)

(12)

147




Net income attributable to controlling interest

$    412,777

$ 278,835


$    691,612


$    378,295

$ 298,267


$    676,562














Effective tax rate

22.9%



27.3%


14.4%



26.7%

Add back interest expense for subordinated










   debt, net of tax

1,300

(1,169)

(13)

131


171



171

Numerator for diluted earnings










 per share

$    414,077

$ 277,666


$    691,743


$    378,466

$ 298,267


$    676,733














Earnings per common share:











Basic earnings per share attributable to controlling interest

$          2.30



$          3.86


$          2.06



$          3.69















Diluted earnings per share attributable to controlling interest

$          2.23



$          3.73


$          1.99



$          3.55














Weighted average shares used in per share calculation:











Basic


179,390



179,390


183,398



183,398


Diluted


185,595



185,595


190,591



190,591




(1)


The Company reports Non-GAAP results which excludes costs that are not indicative of the profitability or cash flows of the Company's ongoing or future operations.  Such costs are restructuring cost, business transformation expenses, amortization and depreciation of deferred revenue, intangibles assets, and fixed assets, and revaluation charges for inventories, contingent consideration liabilities, asset impairments, and in process research and development expenses, incurred as a result of business combinations as well as the impact from the divestiture and discontinuance of product lines.    The Company also excludes noncash interest expense associated with convertible debt bifurcation and noncash charges associated with non-controlling interests. In addition, the Company excludes one-time costs including the early repayment of debt and the associated impacts, and the impact of certain settlements in order to provide a supplemental comparison of the results of operations.




(2)


Adjust for royalty revenue recognized upon a historical and current licensing settlement of $38.8 million, offset with fair value amortization of purchased deferred revenue of $2.9 million and add back revenue related to returns of a discontinued product of $0.9 million for the year ended December 31, 2011.  Add back fair value amortization of purchased deferred revenue of $6.7 million for the year ended December 31, 2010.




(3)


Add back royalty fees and expenses of $4.5 million related to the historical portion of the settlement of a licensing dispute, charges for inventory reserves related to a discontinued product of $2.1 million, and $0.5 million of purchase accounting related cost of revenue revaluation, offset by contingent consideration revaluation of $2.7 million for the year ended December 31, 2011.  Add back noncash charges for purchase accounting inventory revaluation cost of $0.9 million, offset with contingent consideration revaluation of $6.3 million for the year ended December 31, 2010.




(4)


Add back amortization of purchased intangibles and write off of purchased in-process research and development.




(5)


Add back contingent consideration revaluation of $13.7 million, depreciation of purchase accounting property, plant, and equipment revaluations of $7.1 million, $10.0 million for expenses and an asset impairment partially offset by recovery of expenses related to the historical portion of the settlement of a licensing dispute, and accelerated compensation expense related to business acquisitions of $1.5 million for the year ended December 31, 2011.  Add back depreciation of purchase accounting property, plant, and equipment revaluations of $10.4 million and accelerated compensation expense related to business acquisitions of $18.9 million for the year ended December 31, 2010.  




(6)


Add back business consolidation costs.




(7)


Add back charges related to noncash interest expense as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options of $24.6 million and $38.0 million for the years ended December 31, 2011 and 2010, respectively.  Adjust for imputed finance charges of $6.2 million and $1.5 million associated with contingent consideration on business acquisitions for the years ended December 31, 2011 and 2010, respectively.




(8)


Add back loss on early retirement of debt.




(9)


Adjust for gain on divestiture of equity investments.




(10)

Adjust for gain on impaired security recovery of $7.1 million, a discontinuance gain on cash flow hedge of $0.6 million and gain on foreign currency related to joint venture divestiture of $1.0 million offset by loss on discontinuance of cash flow hedge of $12.9 million and joint venture purchase accounting adjustment of $1.2 million for the year ended December 31, 2010.



(11)

Non-GAAP tax differs from GAAP tax expense due to the exclusion of the aforementioned business combination related charges, non cash charges, and one-time costs which are not indicative of the profitability or cash flows of the Company's ongoing or future operations.  These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation.



(12)

Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant, and equipment revaluations attributable to non-controlling interest, net of tax benefit.



(13)

Eliminate noncash interest charges from diluted earnings per share calculation, as the noncash interest is excluded from the calculation of Non-GAAP net income.



LIFE TECHNOLOGIES CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


















For the year



ended December 31,

(in thousands)(unaudited)

2011


2010

Net income

$ 412,119


$ 377,858


Add back amortization and





   share-based compensation

394,326


386,621


Add back depreciation

123,578


122,978


Balance sheet changes

(82,781)


(101,435)


Other noncash adjustments

(38,107)


(46,933)

Net cash provided by operating activities

809,135


739,089


Capital expenditures

(99,293)


(124,817)

Free cash flow

709,842


614,272

Net cash provided by (used in) investing activities

(52,591)


5,013

Net cash used in financing activities

(627,268)


(407,808)

Effect of exchange rate changes on cash

(4,790)


5,505

Net increase in cash and cash equivalents

$   25,193


$ 216,982



LIFE TECHNOLOGIES CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS


















December 31,


December 31,

(in thousands)

2011


2010

ASSETS

(unaudited)



Current assets:





Cash and short-term investments

$         881,994


$        854,801


Trade accounts receivable, net of allowance for doubtful accounts

636,998


587,456


Inventories

377,866


323,318


Prepaid expenses and other current assets

175,222


280,950


    Total current assets

2,072,080


2,046,525






Long-term assets

7,094,346


7,439,674


    Total assets

$      9,166,426


$     9,486,199






LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:





Current portion of long-term debt

$         450,839


$        347,749


Accounts payable, accrued expenses and other current liabilities

989,645


798,636


    Total current liabilities

1,440,484


1,146,385











Long-term debt

2,297,653


2,727,624

Other long-term liabilities

794,778


1,174,161

Equity

4,633,511


4,438,029


   Total liabilities and equity

$      9,166,426


$     9,486,199



SOURCE Life Technologies Corporation

News Provided by Acquire Media